AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Charcot-Marie-Tooth (CMT) neuropathies are a diverse group of peripheral nerve disorders affecting 1 in 2,500 individuals.
• CMT type 1A (CMT1A) is the most common variant, primarily involving Schwann cells (SC).
• Previous studies demonstrated neurotrophin-3 (NT-3) efficacy in mouse models and CMT1A patients, but limitations in half-life and availability hindered long-term treatment.

Purpose of the Study:

• To investigate the potential of NT-3 gene therapy using adeno-associated virus (AAV) delivered to muscle for treating demyelinating CMT.
• To establish intramuscular (i.m.) delivery of rAAV1.NT-3 as a method for sustained NT-3 secretion and therapeutic benefit.
• To identify a suitable muscle-specific promoter and therapeutic dose for effective NT-3 gene therapy.

Main Methods:

• Utilized the trembler(J) (Tr(J)) mouse model of demyelinating CMT.
• Administered rAAV1.NT-3 via intramuscular injection to muscle tissue.
• Measured NT-3 secretion levels in blood.
• Assessed improvements in motor function, peripheral nerve histopathology, and electrophysiology.
• Validated compound muscle action potential amplitude as a surrogate for functional improvement.

Main Results:

• rAAV1.NT-3 therapy in the Tr(J) model led to measurable NT-3 secretion in the bloodstream.
• Therapeutic levels of NT-3 resulted in significant improvements in motor function, nerve histopathology, and electrophysiology.
• Established a therapeutic dose and identified a muscle-specific promoter for sustained NT-3 expression.
• Demonstrated the utility of compound muscle action potential amplitude as a functional outcome measure.

Conclusions:

• Intramuscular delivery of rAAV1.NT-3 is a viable strategy for sustained neurotrophic factor delivery in CMT1A.
• This gene therapy approach offers a promising therapeutic avenue for CMT1A and potentially other peripheral nerve disorders.
• The established methodology serves as a foundation for future clinical trials in CMT1A patients.